<DOC>
	<DOCNO>NCT03081923</DOCNO>
	<brief_summary>Background : The prognosis pt fail multiple chemotherapy ( CT ) regimens quite dismal . PD-L1 frequently express immunohistochemistry ( IHC ) germ cell tumor ( GCT ) . D monoclonal antibody ( mAb ) inhibit bind PD-L1 . T , anti-CTLA4 mAb , immunomodulatory therapy . Combination immunotherapy show improved activity compare monotherapy . The investigator aim investigate activity D , alone combination T , chemorefractory GCT . Trial Design : This open-label , randomize , 3-stage , phase 2 study . Pts fail ≥2 prior CT regimen ( include high-dose CT ) randomize receive one following : D , 1.5 g via IV infusion q4w , total 12 month ( 13 doses/cycles ) alone T , 75 mg IV q4w , start week 0 , 4 month ( 4 doses/cycles ) . Serum tumor marker , compute tomography fluorodeoxyglucose positron emission tomography ( FDG-PET ) scan repeat q8 week . The primary endpoint objective response-rate ( ORR=complete response partial response normal marker ) . H0 : ORR rate ≤10 % , H1 : ORR ≥25 % , type I II error rate 10 % . In stage 1 , 11 pt allocate arm . According Gehan 's rule , trial terminate whenever response observe . 29 additional pt add arm fulfilling stage 1 criterion . ORR ≥7 pt require . In stage 3 , pt stage 1-2 arm retrospectively evaluate Programmed cell Death Ligand-1 ( PD-L1 ) IHC . The Ventana PD-L1 IHC assay use . In case negative finding end stage 2 , target benefit likely occur PD-L1+ pt , study prosecution accordance enrichment strategy undertaken . In particular , predictive power ( PP ) calculate assume expansion PD-L1+ cohort maximum 60 pt . Each arm categorize promising ( PP &lt; 30 % ) promising ( PP ≥30 % ) . The promise one enter stage 3 . Should arm judge promising , one yield ≥20 % PP advantage select ; monotherapy preferred otherwise . Details algorithm use PD-L1 IHC study finalize ( EudraCT number 2016-001688-35 ) .</brief_summary>
	<brief_title>Durvalumab Alone With Tremelimumab Refractory Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Age ≥ 18 year Male female gender . Histological clinical diagnosis GCT . Availability archival tumor sample local assessment ( immunohistochemistry ) PDL1 expression . Either gonadal extragonadal tumor primary . Failure ≥2 prior chemotherapy regimens metastatic disease ( 12 cycle cisplatin , etoposide bleomycin ( PEB ) 1 cycle carboplatin area curve ( AUC ) 7 give adjuvant set clinical stage I disease count prior line ) . Failure highdose chemotherapy allow . Brain metastasis : patient present brain metastasis sole site disease relapse/progression allow enter study . Otherwise , patient metastatic disease include brain metastasis allow provide irradiated , stable least 4 week , washout period steroid occur ( 28 day ) . Subjects must provide write informed consent . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Adequate endorgan system function test . See study full protocol durvalumabspecific tremelimumab requirement . Prior exposure immunemediated therapy , include limited , antiCytotoxic TLymphocyte Antigen4 ( CTLA4 ) , antiPD1 , antiPDL1 , antiPDL2 antibody , include therapeutic anticancer vaccine . Any unresolved toxicity NCI CTCAE Grade ≥2 previous anticancer therapy exception alopecia , vitiligo , laboratory value define inclusion criterion . Patients Grade &lt; 2 neuropathy evaluate casebycase basis consultation Principal Investigator . Patients irreversible toxicity reasonably expect exacerbated treatment durvalumab tremelimumab may include consultation Principal Investigator . Any concurrent chemotherapy , biologic , hormonal therapy cancer treatment . History allogenic organ transplantation require use immunosuppressive agent . Active prior document autoimmune inflammatory disorder . Active infection include active tuberculosis , hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . Current prior use immunosuppressive medication within 28 day first dose durvalumab tremelimumab . Female patient pregnant breastfeed male female patient reproductive potential willing employ effective birth control screen 90 day last dose durvalumab monotherapy 180 day last dose durvalumab + tremelimumab combination therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Testicular cancer</keyword>
</DOC>